Cyclic Nucleotides Differentially Regulate Cx43 Gap Junction Function in Uterine Artery Endothelial Cells From Pregnant Ewes

Bryan C. Ampey, Amanda C. Ampey, Gladys E. Lopez, Ian M. Bird, Ronald R. Magness

Abstract—Cell–cell communication is dependent on GJ (gap junction) proteins such as Cx43 (connexin 43). We previously demonstrated the importance of Cx43 function in establishing the enhanced pregnancy vasodilatory phenotype during pregnancy in uterine artery endothelial cells from pregnant (P-UAEC) ewes. Cx43 is regulated by elevating cAMP and PKA (protein kinase A)–dependent Cx43 S365 phosphorylation–associated trafficking and GJ open gating, which is opposed by PKC (protein kinase C)–dependent S368 phosphorylation-mediated GJ turnover and closed gating. However, the role of cyclic nucleotide-mediated signaling mechanisms that control Cx43 and GJ function in P-UAECs is unknown. We hypothesize that cAMP will mediate increases in S365 phosphorylation, thereby, enhancing GJ trafficking and open gating, while cGMP will stimulate S368, but not S365, phosphorylation to enhance GJ turnover and closed gating in P-UAECs. Treatment with 8-Bromo (8-Br)-cAMP signal significantly (P<0.05) increased nonphosphorylated S365 signal and total Cx43 phosphorylation, but not S368 phosphorylation, while 8-Br-cGMP significantly (P<0.05) increased Cx43 C-terminus-S365 signal, S368, and total Cx43 phosphorylation. Inhibition of PKA, but not PKG (protein kinase G), abrogated the 8-Br-cAMP–stimulated increase in nonphosphorylated S365 and total Cx43 phosphorylation and inhibited S368 below basal levels, whereas inhibition of PKG blocked (P<0.05) the 8-bromo-cGMP-stimulated rises in nonphosphorylated S365, total Cx43, and S368 phosphorylation levels in P-UAECs. Functional studies showed that 8-Br-cAMP increased dye transfer and sustained calcium bursts, while 8-Br-cGMP decreased both. Thus, in P-UAECs, only 8-Br-cAMP and not 8-Br-cGMP effectively enhances nonphosphorylated S365 and total Cx43 expression that correspondingly reduces S368 phosphorylation, allowing increased GJ communication. This provides new insights into the regulatory mechanisms behind Cx43 function and GJ communication. (Hypertension. 2017;70:401-411. DOI: 10.1161/HYPERTENSIONAHA.117.09113.) ● Online Data Supplement

Key Words: calcium • Cx43 • cyclic nucleotides • endothelium • gap junction • pregnancy • vasodilation

Cell to cell communication is vital for the development of cardiovascular adaptations during gestation and are reliant on GJ (gap junction) intercellular communication (GJIC).1,3 GJs are specialized membrane hemichannels composed of Cx (connexin) proteins that direct cell–cell diffusion of ions, small molecules, and second messengers (eg, IP3, Ca2+, cAMP, cGMP, ATP)4-6 that are important for synchronizing endothelial cell vasodilatory responses. Pregnancy is a physiological state of vasodilation that requires heightened cell coupling to maintain substantial increases in blood flow necessary for fetal growth and development.1,2,3 Endothelial-derived vasodilators, such as prostacyclin (PGI2) and nitric oxide (NO), are enhanced in the uterine circulation during pregnancy and serve as a pregnancy-adapted vasodilatory phenotype that sets the stage for the pronounced gestational elevations in uterine blood flow.3,8 We have shown that Cx43 is the major GJ protein present in uterine artery endothelial cells (UAECs) and controls pregnancy-specific Ca2+-mediated activation of endothelial NO synthase and NO production in vitro and ex vivo.2 In hypertensive states of pregnancy, reduced vasodilation is related to endothelial cell dysfunction characterized by reduced bioavailability of endothelium-derived vasodilators, in particular NO.1,2,3 Aberrant Cx43 expression, function,9 and lack of sufficient NO production are associated with hypertension.10 Because endothelial cell dysfunction is linked to impaired endothelium-dependent vasodilation mechanisms, hypertensive diseases of pregnancy, such as pre eclampsia,6,11,12 may very well occur at least in part because of...
a failure to enhance the vasodilatory phenotype through Cx43 closure or internalization.3

Cx43 distribution at the plasma membrane seems to influence the conduction properties of cells.4–6 Cx43 distribution and conductivity are also dictated by phosphorylation by several site-specific signaling kinases.4,5,13–18 Phosphorylation of Cx43 at cAMP-dependent PKA (protein kinase A)–mediated serine (S)365 and PKC (protein kinase C)–dependent S368 sites differentially regulate GJIC via open16,19 and closed17,20 gating of GJ hemichannels, respectively. The S365 and S368 sites also differentially regulate GJ assembly and disassembly at the plasma membrane, respectively.16–20 The second messenger cAMP via PKA increases Cx43 phosphorylation at S365 and GJIC. The cAMP-enhanced GJ assembly directly results in the net movement of newly synthesized Cx43 to the plasma membrane,16,18,19 thereby, rapidly increasing the number and assembly of de novo GJs within minutes.19 In addition, cGMP-dependent Cx43 phosphorylation decreases GJ conductance,21 while PKC-dependent S368 phosphorylation decreases GJIC and dramatically inhibits new GJ assembly.22,23 The interaction between phosphorylation state at S365 and S368 inversely affects each other and is suggested to be mutually exclusive. This is known as the gatekeeper theory, where phosphorylated S365 plays a gatekeeper role by preventing Cx43 phosphorylation at S368. Thus, S365 phosphorylation may function to protect cells from downregulation of GJIC.5,24

Although cAMP and cGMP signaling is usually thought of as mutually redundant, it is possible that cAMP/PKA and cGMP/PKG (protein kinase G) pathways will have opposing functional effects on Cx43. To date, there is a lack of an understanding of their mutual roles in Cx43 phosphorylation and signaling events that affect vasodilatory processes in UAECs. In these studies, we, thus, contrasted cAMP and cGMP effects on (1) Cx43 phosphorylation state in nonpregnant (NP)-UAECs versus P-UAECs; (2) Cx43 phosphorylation state that occurs via PKA or PKG in P-UAECs; and (3) changes in Cx43 expression and phosphorylation that also correspondingly drive changes in GJIC communication and sustained calcium bursts in P-UAECs. We hypothesize that cAMP will mediate increases in Cx43 S365 phosphorylation that will enhance GJ trafficking and open gating, while cGMP will increase S368, but not S365, phosphorylation to enhance GJ turnover and closed gating in P-UAECs versus NP-UAECs.

Materials and Methods

Detailed methods are available in the online-only Data Supplement.

Cell Preparation and Culture

University of Wisconsin-Madison Animal Care Committee approved these protocols. Ovine UAECs were isolated from nonpregnant (luteal, n=4) and pregnant (120–130 days; term=147 days; n=4) ewes.1 Passage 4, UAECs (>90% confluent) were cultured in endothelial basal medium containing 1% FBS and 1% streptomycin/penicillin, or 1% fetal bovine serum (FBS), 1% streptomycin/penicillin, or 1% horse serum, 1% streptomycin/penicillin, or 1% fetal bovine serum, 1% streptomycin/penicillin, and 0.1% amphotericin B for Cx43 staining.

Experimental Treatments and Protein Kinases Inhibition

For exogenous cyclic nucleotide time course experiments, NP-UAECs and P-UAECs were treated with endothelial basal medium or endothelial basal medium containing 1 μmol/L or 1 mmol/L of 8-bromo (8-Br)-cAMP or 8-Br-cGMP for 0 to 60 minutes or 12 hours. Based on these studies, P-UAECs were treated for 1 hour with cell-permeable 10 μmol/L of antagonists for PKA (PKI [protein kinase inhibitor] 14–22 amide, myristoylated) and PKG [2-Bromo-3,4-dihydro-3-[3,5-O-[(R)-mercaptoposphinylidene]-β-n-ribofuranosyl]-6-phenyl-9H-imidazo[1,2-a]purin-9-one sodium salt] (R-8-Br-PET-CGMP) followed by treatment with doses of either 1 μmol/L or 1 mmol/L of 8-Br-cAMP or 8-Br-cGMP for 30 minutes.

Protein Extraction and Western Immunoblotting

Western analyses were performed1 on whole cell lysates using antibodies for Cx43 C-terminus (CT1) S365 antibody (1:3000) specific to phosphorylated at serine 368, or total Cx43 when it is nonphosphorylated at S365 (online-only Data Supplement). S368 (1:1250) detects levels of Cx43 only when phosphorylated at serine 368, or total Cx43 (1:3000). Secondary antibodies, anti-rabbit or anti-mouse, were detected using enhanced chemiluminescence and HyperFilm. β-Actin was used as a loading control.2,3

Lucifer Yellow Dye Transfer

P-UAECs (<90% confluent) were grown on chamber slides1 and treated for 1 hour with 10 μmol/L PKI 14–22 amide, myristoylated, or Rp-8-Br-PET-CGMPs prior to treatment with vehicle or either 1 μmol/L or 1 mmol/L 8-Br-cAMP or 8-Br-cGMP for 30 minutes. UAECs were scraped with a sterile razor blade and incubated for 10 minutes with 0.05% Lucifer yellow and tetramethylrhodamine dextran (3 kDa),1,2,25 washed with Ca2+-free Krebs buffer containing an additional 50 μmol/L ethylene glycol tetraacetic acid,1,3 and imaged in triplicate using fluorescence microscope. Areas of dye spread (fluorescent areas) were quantified using ImageJ software.

Fura-2 [Ca2+] Imaging Studies

P-UAECs were grown to >90% density, loaded with Fura-2AM (10 μmol/L) in Krebs buffer (125 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgSO4, 1 mmol/L KHPO4, 6 mmol/L glucose, 2 mmol/L CaCl2, 25 mmol/L HEPES, pH 7.4), and individual endothelial cells (≥90 cells/dish) were preloaded and imaged. Cells were recorded simultaneously for a 5-minute baseline and then stimulated by ATP (100 μmol/L; 30 minutes).1 Cells were washed and allowed to recover for 20 minutes and treated with 8-Br-cAMP or 8-Br-cGMP (1 μmol/L or 1 mmol/L; 30 minutes) before a subsequent treatment of ATP while recording continued (another 30 minutes). Cells that gave ≥2 Ca2+ bursts during the initial ATP treatment were counted before and after treatment as described previously.1

Statistical Analysis

Data presented as means±SEM fold of control (untreated). We performed statistical analyses between control and experimental groups using the Student’s t-test, 1-way analysis of variance, 2-way analysis of variance, or a Mann–Whitney rank-sum test as appropriate (SigmaPlot12). Statistical significance was established a priori at P<0.05.

Results

Effects of Cyclic Nucleotides on Cx43 Phosphorylation in UAECs

Using Western analysis, we examined Cx43 phosphorylation sites (S365 and S368) that may act inversely to control GJ assembly/disassembly and gating. Compared with NP-UAECs and untreated control, P-UAECs treated with 1 μmol/L and 1 mmol/L 8-Br-cAMP exhibited significant pregnancy-specific increases in CT1 S365 levels (nonphospho-specific antibody) of 3-fold and 5-fold (P<0.05) by 30 minutes, which maintained for ≤12 hours (∼2- to 3-fold; Figure 1A). In contrast, 8-Br-cAMP treatment only promoted a modest rise in Cx43 S368 phosphorylation signal (Figure 1B), which did not reach statistical significance, consistent with PKA regulating S365 and not
the pS368. Interestingly, 1 μmol/L 8-Br-cAMP increased total Cx43 ≈2-fold by 60 minutes, while the 1 mmol/L dose significantly increased total Cx43 4-fold by 30 minutes, an increase maintained for ≤12 hours (P<0.05; Figure 1C). When P-UAEC S365 and pS368 data were normalized to total Cx43 (Figure 1D), P-UAECs incubated with 1 mmol/L 8-Br-cAMP still displayed an overall increase in Cx43 S365 signal that is most likely caused by the substantial new synthesis of nonphosphorylated Cx43 protein. Because of this increase in total Cx43, the normalized pS368 Cx43 data displayed a relatively smaller, but still significant increase in CT1 S365 signal and an overall decrease (P<0.05) in Cx43 S368 phosphorylation.

Figure 1. Effects of 8-Br (8-Bromo)-cAMP on Cx43 (connexin 43) phosphorylation in nonpregnant uterine artery endothelial cells (NP-UAECs) and pregnant uterine artery endothelial cells (P-UAECs). 8-Br-cAMP significantly increases nonphosphorylated Cx43 S365 levels, but not pS368. Western blot analyses showing the effects of 1 μmol/L and 1 mmol/L 8-Br-cAMP for 0 to 60 minutes or 12 hours in NP-UAECs vs P-UAECs on (A) nonphosphorylated Cx43 S365 levels detected by the Cx43 C-terminus (CT1) antibody, (B) Cx43 pS368 phosphorylation levels, (C) total Cx43 levels, and (D) Cx43 S365 and pS368 phosphorylation sites normalized to total Cx43 only for P-UAECs treated with 1 mmol/L 8-Br-cAMP. *, Increase (P<0.05, n=4) of cyclic nucleotide treatment vs untreated control. **, Decrease (P<0.05, n=4) of S365/total Cx43 vs pS368/total Cx43. t, Increase (P<0.05, n=4) of Cx43 phosphorylation in 1 mmol/L vs 1 μmol/L treatment. #, Increase (P<0.05, n=4) of Cx43 phosphorylation in NP-UAEC- vs P-UAEC-treated cells. +, Increase (P<0.05, n=4) of S365/total Cx43 vs pS368/total Cx43.
magnitude (≈2-fold; 30 minutes) than 8-Br-cAMP (Figure 2A). In contrast to 8-Br-cAMP, 8-Br-cGMP also significantly increased Cx43 S368 phosphorylation levels (3- to 4-fold; 30 minutes; \( P < 0.05 \); Figure 2B). While 8-Br-cGMP also displayed both a time- and dose-related increase in total Cx43 (Figure 2C), when the S365 and pS368 signals were normalized to total Cx43 levels in P-UAECs, there was no significant increase (\( P > 0.05 \)) in S365 signal or significant decrease in pS368 signal (Figure 2D).

**Role of PKA or PKG in Mediating Cx43 Phosphorylation in P-UAECs**

To test the role of PKA and PKG, we used kinase-specific inhibitors. We observed that P-UAECs treated with the PKA

![Figure 2](http://hyper.ahajournals.org/)

**Figure 2.** Effects of 8-Br (8-Bromo)-cAMP on Cx43 (connexin 43) phosphorylation in nonpregnant uterine artery endothelial cells (NP-UAECs) and pregnant uterine artery endothelial cells (P-UAECs). 8-Br-cGMP significantly increases both nonphosphorylated Cx43 S365 and pS368 levels. Western blot analysis showing the effects of 1 μmol/L and 1 mmol/L 8-Br-cGMP for 0 to 60 minutes or 12 hours in NP-UAECs vs P-UAECs on (A) nonphosphorylated Cx43 S365 levels detected by the Cx43 C-terminus (CT1) antibody, (B) Cx43 pS368 phosphorylation levels, (C) total Cx43 levels, and (D) Cx43 S365 and pS368 phosphorylation sites normalized to total Cx43 only for P-UAECs treated with 1 mmol/L 8-Br-cGMP. *, Increase (\( P < 0.05, n=4 \)) of cyclic nucleotide treatment vs untreated control. t, Increase (\( P < 0.05, n=4 \)) of Cx43 phosphorylation in 1 mmol/L vs 1 μmol/L treatment. #, Increase (\( P < 0.05, n=4 \)) of Cx43 phosphorylation in NP-UAEC- vs P-UAEC-treated cells.
antagonist, PKI, alone significantly reduced CT1 S365 signal and total Cx43 levels and pS368 Cx43 phosphorylation. PKI treatment prevented 8-Br-cAMP-mediated increases and significantly reduced CT1 S365 (nonphosphorylated at S365), Cx43 pS368, and total Cx43 signals below basal (Figure 3A through 3C). PKI also inhibited the lesser 8-Br-cGMP-induced effects on the CT1 S365 signal and reduced total Cx43 levels below basal, consistent with a possible cross reaction or cross talk of 8-Br-cGMP with PKA. PKI treatments did not significantly alter the pS368 signal in 8-Br-cGMP-treated P-UAECs, in contrast to the significant (P<0.05) inhibition below basal when 8-Br-cAMP treatment was used (Figure 3B).

Use of the PKG inhibitor Rp-8-Br-PET-cGMPs alone appeared to not affect CT1 S365 signal (Figure 4A) or changes in pS368 Cx43 (Figure 4B) or total Cx43 (Figure 4C). Rp-8-Br-PET-cGMPs also failed to prevent 8-Br-cAMP-stimulated increases in CT1 S365 signal or total Cx43 in P-UAEC (Figure 4A and 4C). However, Rp-8-Br-PET-cGMPs blocked (P<0.05) 8-Br-cGMP-stimulated increases in CT1 S365 signal and total Cx43 (Figure 4A and 4C) and successfully blocked 8-Br-cGMP effects on S368 phosphorylation levels in P-UAECs (Figure 4B). Thus, these inhibitors successfully discriminated the roles of PKA versus PKG in each response at the dose used.

Role of Cyclic Nucleotides Signaling Pathways in Regulating GJIC Function

Using Lucifer yellow dye transfer as a measure of GJIC and GJ functionality, we examined the role cyclic nucleotides play in GJIC. Under these conditions, there was no detectable difference in basal GJIC between NP-UAEC and P-UAEC (Figure 5A). P-UAECs incubated with 1 mmol/L 8-Br-cAMP (30 minutes) increased GJIC. However, selective inhibition of PKA using PKI, but not by PKG inhibitor Rp-8-Br-PET-cGMPs, completely abrogated GJIC stimulated by 8-Br-cAMP (Figure 5B). P-UAECs treated with 1 mmol/L 8-Br-cGMP decreased dye transfer (Figure 5C), but neither PKA nor PKG inhibitors (PKI and Rp-8-Br-PET-cGMPs) had an effect on 1 mmol/L 8-Br-cGMP-induced changes in GJIC (Figure 5C).

![Figure 3](http://hyper.ahajournals.org/)

**Figure 3.** Role of PKA (protein kinase A) signaling pathways in Cx43 (connexin 43) phosphorylation in pregnant uterine artery endothelial cells (P-UAECs). Inhibition of PKA significantly reduced nonphosphorylated Cx43 S365 levels. Western blot analysis showing the effects of treatment with 10 μmol/L of PKA antagonist PKI (1 hour) on 1 μmol/L and 1 mmol/L 8-Br (8-Bromo)-cAMP-mediated and 8-Br-cGMP-mediated (30 minutes) changes of (A) nonphosphorylated Cx43 S365 levels detected by the Cx43 C-terminus (CT1) antibody, (B) Cx43 pS368 phosphorylation levels, and (C) total Cx43 levels. *, Decrease (P<0.05, n=4) in Cx43 phosphorylation state vs untreated control.
Cyclic Nucleotides Differentially Regulate Sustained-Phase [Ca2+]i Responses

In light of the Western analysis and direct GJIC studies above, we further investigated whether the cAMP- and cGMP-mediated control of Cx43 phosphorylation and GJIC is reflected by changes in ATP-induced sustained Ca2+ bursting that mediate the enhanced and sustained NO production in P-UAEC1,2 and subsequently the vasodilatory phenotype or P-UAECs that we recently defined.3 Although repeated doses of ATP itself show modest reductions in subsequent Ca2+ bursting by ≈10%, the pretreatment with cAMP completely abrogated this (Figure 6). Indeed, compared with control burst numbers, P-UAECs exposed to 1 μmol/L and 1 mmol/L 8-Br-cAMP increased the number of ATP-mediated sustained Ca2+ bursts by 5.4% and 27.9%, respectively (P<0.01). Conversely, treatment with 1 μmol/L 8-Br-cGMP led to a slight but not significant elevation (2.9%) in Ca2+ bursting, while 1 mmol/L 8-Br-cGMP significantly inhibited [Ca2+]i bursts by 11.5% less than control (P<0.05). This level is similar to ATP-mediated Ca2+ bursts previously observed in NP-UAECs,1 but greater than those seen when GAP27 was used to block Cx43-mediated activity and NO production.1,2

Discussion

Previously, we demonstrated the importance of Cx43 function in establishing the enhanced pregnancy vasodilatory phenotype of UAECs during pregnancy that includes increases in cyclic nucleotides.1-3,7,13 This process is highlighted by the requirement of a functional Cx43 GJs for normal pregnancy-enhanced Ca2+ responses to increase NO production.1,2 Accumulating evidence has shown that cAMP plays an important regulatory role in Cx43 expression and functionality in many cell types,15 yet there are few reports investigating a role for cAMP versus cGMP in regulating Cx43 in endothelial cell function during the pregnancy state. In this report, we investigated the involvement

Figure 4. Role of PKG (protein kinase G) signaling pathways in Cx43 (connexin 43) phosphorylation in pregnant uterine artery endothelial cells (P-UAEcs). Inhibition of PKG did not affect Cx43 phosphorylation. Western blot analysis of the effects of 10 μmol/L of PKG antagonist Rp-8-Br (8-Bromo)-PET-cGMPS (1 hour) on 1 μmol/L and 1 mmol/L 8-Br-cAMP-mediated and 8-Br-cGMP-mediated (30 minutes) changes of (A) nonphosphorylated Cx43 S365 levels detected by the Cx43 C-terminus (CT1) antibody, (B) Cx43 pS368 phosphorylation levels, and (C) total Cx43 levels. *, Increase (P<0.05, n=4) in Cx43 phosphorylation state vs untreated control.
Ampey et al  
Cyclic Nucleotides Regulate Gap Junction Function  
407

of the classical cAMP/PKA and the lesser-studied cGMP/PKG signaling pathway on Cx43 phosphorylation states of sites S365 and S368 that are associated with GJ assembly/disassembly and gating and function in UAECs during pregnancy. The key findings of the present study are: (1) pregnancy-specific P-UAEC Cx43 phosphorylation state is differentially regulated by both cyclic nucleotides; (2) cAMP/PKA activation mediates a rise in CT1 nonphosphorylated Cx43 S365 signal; (3) cGMP/PKG pathway stimulates a greater rise in S368 phosphorylation; and (4) overall, PKA specifically regulates in vitro increases in ATP-stimulated GJIC function and sustained phase [Ca2+]i responses that are necessary for enhanced NO production in normal pregnancy, while PKG can oppose these actions through Cx43 S368 phosphorylation. Therefore, this study provides the first direct evidence for the mechanistic basis of the cAMP-mediated and cGMP-mediated signaling pathways opposing each other and that cAMP increases the rapid appearance of new Cx43 protein, for reasons that have yet to be determined, to regulate gap junctional communication in UAECs from the pregnant state.

In the current study, we were surprised to observe that in exposing UAECs to 8-Br-cAMP and 8-Br-cGMP, both cyclic nucleotides decreased S365 signaling in P-UAECs. However, only 8-Br-cAMP stimulated a net decrease in S365 signaling, especially in a pregnancy-specific fashion because this was not observed in NP-UAECs. Most reports studying 8-Br-cAMP actions on S365 signaling found an increase in S365 phosphorylation and not the net decrease as we observed. Others have reported that the CT1 Cx43 antibody preferentially recognizes predominantly nonphosphorylated S365 that is newly synthesized in the Golgi complex and not present in Cx43 GJ plaques in the plasma membrane. In this regard, our data show that 8-Br-cAMP caused a rapid appearance of newly synthesized nonphosphorylated Cx43 protein. We also observed that 8-Br-cAMP did not increase the S368 phosphorylation that previous reports have shown correlates with reduced GJIC, channel conductance, and half-life. This observation is consistent with other studies that demonstrated that 8-Br-cAMP did not have any effects on the PKC-sensitive phosphorylation site S368. Moreover,
Hypertension August 2017

reports have described S365 as the gatekeeper that prevents S368 phosphorylation until S365 is dephosphorylated, thus, showing that phosphorylation and dephosphorylation events contribute to GJIC. Remarkably, because of the 8-Br-cAMP-stimulated decreases in S365 signal, we expected a corresponding increase in S368 phosphorylation; however, this was not the case. Of note, these present data in P-UAECs, however, is not fully consistent with this hypothesis. Using the CT1 Cx43 antibody, we provide direct evidence that 8-Br-cAMP promotes a substantial increase in total Cx43 and net decrease in S365 phosphorylation, but also shows little increase in absolute S368 phosphorylation and a concurrent decrease in overall S368 phosphorylation in P-UAECs. This is the first report showing that 8-Br-cGMP can also increase the availability of newly released Cx43 in P-UAECs or in any cell type. However, we caution that we only saw this increase by 8-Br-cGMP with the higher 1 mmol/L dose. Selective kinase antagonist studies suggest that 8-Br-cGMP stimulation of PKA at these higher doses or cross talk through cGMP-mediated inhibition of phosphodiesterase PDE3, subsequently increasing cAMP levels, may have occurred. Cross talk between the different kinases via phosphodiesterases has been reported in consideration of the NO/cGMP signaling cascade. Yao et al previously reported that activation of the NO/cGMP pathway increases GJIC and Cx43 expression acting through PKA activity. We also show that 8-Br-cGMP has less effect on new protein synthesis or overall S365 phosphorylation and yet increases Cx43 S368 phosphorylation beyond any effect of 8-Br-cAMP. Indeed, this increase in S368 phosphorylation parallels most closely the cGMP-stimulated rises in total Cx43. Thus, while an increase in newly synthesized proteins, presumably devoid of Cx43 S365 phosphorylation, may be available for S368 phosphorylation, this scenario would fit the gatekeeper hypothesis. The fact that both 8-Br-cAMP and 8-Br-cGMP can stimulate substantial increases in new Cx43 protein, but have different outcomes at pS368, suggests that the hypothesis that phosphorylation of sites S365 and S368 are mutually exclusive may not be the only determinant of Cx43 function in P-UAECs. Other studies have suggested that an initial PKA activation may even accelerate subsequent PKC phosphorylation of Cx43 in other cell types. However, considering our own data, this was not the case as it relates to our results in response to 8-Br-cAMP. It would seem that, even in the face of increased total Cx43 with both 8-Br-cAMP and 8-Br-cGMP, the maintenance of S368 phosphorylation by 8-Br-cGMP otherwise seen to decline with 8-Br-cAMP is enough to prevent any immediate functional advantage.

In addition to the role of cyclic nucleotides in Cx43 regulation, we also present evidence that specific kinases play...
an important role in Cx43 phosphorylation. Several reports have shown that increased cAMP increases Cx43 expression, function, and phosphorylation, and specifically PKA seems to mediate the increase in Cx43 expression. The finding that the PKA antagonist inhibits the effects of 8-Br-cAMP on S365, pS368, and total Cx43 confirms that changes in total Cx43 are PKA-mediated and possibly that mass action of such new protein synthesis is the single greatest force that underlies observed changes in phosphorylation at S365 and at S368. The present finding that 8-Br-cAMP also drives parallel increases in nonphosphorylated S365 and total Cx43 is in agreement with several reports that cAMP events are associated with an increased Cx43 export to the plasma membrane, incorporation into functional GJs, and open gating via PKA-sensitive mechanisms. The inability of 8-Br-cAMP to overcome PKA inhibition and return responses to levels higher than the control is consistent with PKI being an effective and specific inhibitor of PKA and further confirms that PKA also primarily regulates the basal state of Cx43 in P-UAECs. Interestingly, we also show that cGMP is not protective against PKA inhibition. As described earlier, cGMP may be able to compensate for cAMP inhibition in other cell types, but in P-UAECs, it would seem that normally PKA alone positively regulates Cx43. We also show that PKG inhibition had little or no effect on 8-Br-cAMP-induced changes in total Cx43 or Cx43 phosphorylation levels, but did block the effects of 8-Br-cGMP, including on S368 phosphorylation. This observation is consistent with reports that PKG activation has similar effects to PKC-dependent signaling on Cx43 expression and GJIC, suggesting cGMP negatively regulates Cx43 trafficking and GJ plaques in the plasma membrane in a manner not seen for cAMP.

Although 8-Br-cAMP and 8-Br-cGMP both independently increased Cx43 phosphorylation alone, it was only with 8-Br-cAMP that significantly decreased net S365 signal and increased ATP-mediated GJIC and Ca2+ bursts. Functionally, we previously reported that P-UAECs and NP-UAECs exhibit the same expression levels of Cx43, but that P-UAECs show greater ATP-stimulated Cx43 GJ function, which we confirm here in this study. Moreover, we have previously shown that inhibition of Cx43 completely abrogates ATP-induced Ca2+-mediated rises in NO production, a hallmark part of the pregnancy-enhanced vasodilatory phenotype. Several reports have shown that increased cAMP increases Cx43 functionality, as well as expression and phosphorylation, indicating that GJIC and Cx43 phosphorylation are tightly regulated. Specifically, PKA mediates increases in Cx43 expression, and other studies have reported that cAMP/PKA pathway regulates GJIC. We now demonstrate herein for the first time that cAMP/PKA signaling pathway regulates dye transfer and relative ATP-induced Ca2+ bursting in P-UAECs, which is consistent with studies where cAMP-stimulated Cx43 phosphorylation promotes greater GJIC and the number and size of GJ plaques. Consistent with other reports, treatments with 8-Br-cAMP increased GJIC; however, we show in the present study that PKA (not PKG) inhibition specifically abrogated cAMP-induced rises in GJIC. These data further confirm in P-UAECs that the classical cAMP/PKA signaling pathway primarily increases GJIC, perhaps, by way of both increased GJ open gating and new Cx43 protein availability and translocation through the Trans Golgi Network, without a substantial absolute or relative increase in Cx43 S365. Indeed, the overall slight reduction in S365 is paralleled by a greater decrease in inhibitory S368 phosphorylation, demonstrating that GJIC control by cAMP and cGMP is dependent on different site-specific Cx43 phosphorylation profiles. Thus, physiologically, PKA may be a proximal stimulus of endothelial vasodilatory phenotype and function because it may accelerate the relative delivery of newly available Cx43 to the plasma membrane and facilitate open gating, while free of Cx43 S368 inhibitory phosphorylation. Notably, PKG inhibition failed to exert noticeable effects on GJIC, while exogenous treatment with 8-Br-cGMP decreased GJIC below the pregnant control levels. Although 8-Br-cGMP has been observed to increase GJIC in other tissues, similar effects on GJIC were not observed in the current or others studies. It is noteworthy that the differences observed in 8-Br-cGMP-mediated GJIC may be because of treatment times. In our study, we used 8-Br-cGMP acutely for 30 minutes, whereas others reported observed increases in GJIC after a 24-hour period. The purpose of using a shorter time point was to avoid potential changes in Cx43 expression levels and to investigate if rapid phosphorylation of Cx43 coincided with changes in GJIC. In addition, although the 1 mmol/L dose of 8-Br-cAMP increased Cx43 phosphorylation, only the 1 mmol/L dose changed GJIC. This may be because of increased cross talk because of the higher concentration of cyclic nucleotides or possibly by a much smaller mass action effect in our cell type.

While the uterine artery endothelium expresses an abundance of Cx43 protein, Cx43 function is far more related to Cx43 phosphorylation state and location within GJs. Changes in Cx43 function controls communication between cells, and states of high Cx43 connectivity are a part of pregnancy adaptations of endothelial cell function. The biggest adaptations occur within the uterine artery endothelium where increases in ATP-stimulated sustained Ca2+ bursting and NO output occur. However, endothelium adaptations in the systemic and fetal arteries and veins may also occur to different degrees. Furthermore, hypertensive disorders of pregnancy such as preeclampsia are associated with a loss of sustained Ca2+ signaling in both the uterine and systemic vasculature and possibly a decrease in cyclic nucleotide production. Because the uterine artery endothelium exhibits pregnancy-specific endogenous rises in prostacyclin, NO, cAMP, and cGMP production compared with the systemic vasculature, this reinforces the importance of enhanced GJ function via cAMP, as described herein. Overall, our data suggest that 8-Br-cAMP causes a decrease in S365 signal because of a rapid appearance in newly synthesized Cx43 for reasons that have yet to be determined, which was exceeding PKA-mediated phosphorylation of existing Cx43. This study further implicates cAMP/PKA and cGMP/PKG pathways in the differential modification of Cx43 phosphorylation sites.
associated with the assembly/disassembly and gating of GJs, as well as linked to GJ communication and function.

Perspectives

The tightly regulated GJ cell–cell communication process by the actions of cAMP/PKA and cGMP/PKG pathways that inversely modulate both Cx43 phosphorylation and GJ functionality during pregnancy were specifically defined. Previously, studies demonstrated the importance of Cx43 function in regulating vasodilatory pathways, including ATP-induced Ca2+-mediated endothelial NO synthase activation and NO production. We report herein that the specific actions of cAMP, but not cGMP, mediate the vasodilatory phenotype in P-UAECs. These current data suggest that cAMP stimulates both the rapid increase in de novo Cx43 trafficking to the membrane and the open gating associated with a rise in GJIC, while cGMP serves to increase the capacity of P-UAECs to respond to stimuli, but not to an immediate increase in function. Such processes increase P-UAECs capacity to enhance vasodilatory phenotypes during pregnancy to maintain rises in uterine blood flow. Further direct studies of Cx43 trafficking, assembly, and function would be of value to identify how pregnancy-specific vasodilatory mechanisms fail in hypertensive diseases of pregnancy, such as preeclampsia.

Acknowledgments

We thank Mayra B. Pastore, Rosalina Villalon-Landeros, Vladimir E. Vargas, Chi Zhou, S. Omar Jobe, Jason L. Austin, Terrance M. Phernetton, Gladys E. Lopez, Cindy Goss, and Jessica H. Youngblood. We thank Dr Paul Lampe at the Fred Hutchinson Cancer Research Center for the Cx43 CT1-antibody.

Sources of Funding

This work was supported by National Institutes of Health (NIH) P01HD38843, HL49210, HL87144, HL117341 (R.R. Magness), R25-GM083252 (M.L. Carnes), and T32-HD041921 (I.M. Bird).

Disclosures

None.

References


**Novelty and Significance**

**What Is New?**

- cAMP/PKA (protein kinase A), but not cGMP/PKG (protein kinase G), regulate enhanced connexin 43 trafficking and function at the plasma membrane to increase the capacity for pregnancy in uterine artery endothelial cell cell-cell communication during pregnancy.

- cAMP/PKA signaling pathway regulate the pregnancy-specific vasodilatory phenotype associated with elevations in ATP-induced Ca²⁺-mediated endothelial nitric oxide synthase phosphorylation and nitric oxide production.

**What Is Relevant?**

- cAMP/PKA-mediated enhancement of gap junction intercellular communication is a uterine artery endothelial cells pregnancy-specific process to maintain nitric oxide-mediated elevations in uterine blood flow and other vasodilatory phenotypes. Understanding gap junction regulation gives more insight of the mechanisms controlling normal uterine blood flow during gestation, which may be dysfunctional in preeclampsia.

**Summary**

These findings demonstrate that in the uterine vasculature during pregnancy, cAMP and not cGMP signaling processes promote connexin 43 trafficking to the endothelial plasma membrane and gap junction open gating to increase gap junction intercellular communication associated with the enhanced pregnancy-specific vasodilatory phenotype to maintain sufficient uterine blood flow.
Cyclic Nucleotides Differentially Regulate Cx43 Gap Junction Function in Uterine Artery Endothelial Cells From Pregnant Ewes
Bryan C. Ampey, Amanda C. Ampey, Gladys E. Lopez, Ian M. Bird and Ronald R. Magness

Hypertension. 2017;70:401-411; originally published online May 30, 2017;
doi: 10.1161/HYPERTENSIONAHA.117.09113
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/70/2/401
Free via Open Access

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2017/05/30/HYPERTENSIONAHA.117.09113.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/
Cyclic Nucleotides Differentially Regulate Cx43 Gap Junction Function in the Ovine Uterine Endothelium during Pregnancy

Bryan C. Ampey, Amanda C. Ampey, Gladys E. Lopez, Ian M. Bird, and Ronald R. Magness

1 Department of Ob/Gyn, Perinatal Research Labs University of Wisconsin, Madison, Wisconsin
2 Department of Ob/Gyn, University of South Florida, Perinatal Research Center Tampa, FL

Correspondence:
Ronald R. Magness, PhD,
University of South Florida, Department of Ob/Gyn, Perinatal Research Center
++ Current Address: 12901 Bruce B Down Blvd MDC48
Tampa, Florida 33612
Phone: (813) 974-8942
Fax: (608) 257-1304
E-mail: rmagness@health.usf.edu

“In Preparation for Hypertension”

Short Title: Cyclic Nucleotides Regulate Gap Junction Function
Keywords: Gap Junction, Cx43, Cyclic Nucleotides, Pregnancy, Endothelium, Vasodilation

Expanded Methods

**Cell Preparation - UAEC Isolation:** The University of Wisconsin-Madison research animal care committees of the Medical School and the College of Agriculture and Life Sciences approved all procedures and protocols for animal handling and experiments which follow the recommended American Veterinary Medicine Association guidelines for humane treatment and euthanasia of laboratory farm animals. Uterine arteries were obtained from mixed Western breed nonpregnant sheep (n = 6-10) and pregnant ewes at 120–130 days gestation (n=6-10) during nonsurvival surgery as previously described. Uterine arteries were dissected free of connective tissue, fat, and veins. Arteries were rinsed free of blood using medium 199 before tying off arterial branches, clamping off the larger diameter end, and inflating with medium 199 containing 5 mg/ml collagenase B (Roche Molecular Biochemicals) and 0.5% BSA through a three-way stop cock tap. Digestion was allowed to proceed at 37 °C for 55 minutes before flushing the collagenase solution and endothelial cell sheets from the inner surface of the vessel.

**Cell Culture:** Freshly isolated cells (passage 0) were plated to 35-mm dishes in MEM containing 20% FBS, 1% penicillin-streptomycin, and 1% geneticin (growth medium; used throughout). Cells were grown for 6 days and passaged (passage 1) to 60-mm dishes. Cells were grown to approximately 70% confluence and then passaged (passage 2) to T75 flasks. Cells were again grown to approximately 70% confluence and passaged once more (passage 3) to medium containing 10% dimethylsulfoxide and frozen in liquid nitrogen for long term storage. Cells were later recovered and grown in T75 flasks to about 70% confluence and passaged once more (passage 4) as previously described.

**Lucifer Yellow Dye Transfer:** To study cell-cell communication, cells were grown to confluence on Lab-Tek II chamber slides with glass coverslips (Thermo Scientific) treated for 30 minutes with either 1μmol/L or 1mmol/L 8-Br-cAMP or 8-Br-cGMP alone or for 1 hour with 10μmol/L of PKA inhibitor (PKI) or PKG inhibitor (Rp-8-Br-PET-cGMPs) prior to treatment with vehicle or cyclic nucleotides for 30 minutes. Cells were scraped at several sites with a sterile razor blade and incubated for 10 minutes in the dark at room temperature with 0.05% Lucifer yellow and tetramethylrhodamine (TMR) dextran (3KDa) (Molecular Probes) dissolved in Modified Ca$^{2+}$ free Krebs buffer (125 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgSO4, 1 mmol/L KH2PO4, 6 mmol/L glucose, 2 mmol/L CaCl2, and 25 mmol/L HEPES, pH 7.4) containing an additional 50 μmol/L ethylene glycol tetraacetic acid (EGTA). Cells were rinsed four times with Ca$^{2+}$-free Krebs/50 μmol/L EGTA buffer and images were captured using a Nikon Eclipse TE 2000U inverted fluorescence microscope and analyzed with Spot Advanced software (v.4.6, Diagnostic Instruments) to determine the amount of Lucifer yellow dye (“green” cell layers) but not TMR red dye (“red” cell layers) that moved through gap junctions from neighboring loaded cells. Experiments were repeated in triplicate per setting.

**Western Analysis:** Cultured P-UAECs were solubilized directly into lysis buffer [150 mM NaCl, 50 mM Tris-HCl, 10 mM EDTA (pH 7.4), 0.1% Tween-20, 0.1% β-mercaptoethanol, 0.1 mM phenylmethylsulfonylfluoride, 5μ g/ml leupeptin, and 5 μg/ml aprotinin]. Solubilized protein
was quantified using a modified Lowry assay procedure (Bio-Rad Laboratories, Inc., Hercules, CA). Protein samples (30 μg/lane) were separated in size on 4-20% gradient polyacrylamide gels by Tris-HCl gel electrophoresis (100 V, 2.5 h; Mini Protean II, Bio-Rad Laboratories, Inc.) alongside positive controls, and Rainbow molecular weight markers (Bio-Rad Laboratories, Inc.) and transferred to a PVDF membranes (100 V, 2 h) as previously described 1. Proteins (equal volume) were boiled for 2 minutes, followed by electrophoresis on a 4-20% Tris-HCl gel (BioRad; Hercules, CA) for 90 minutes at 150V. Separated proteins were then electrically (60 minutes, 100V) transferred to a PVDF membrane. Antiserum incubations were all performed at room temperature. The antibody, Cx43 CT1, was prepared against amino acids 360–382 of Cx43 was provided by Dr. Lampe as described 5. Antiserum dilutions were as follows: CT1 (Fred Hutchinson Cancer Research Center Hybridoma Development Facility, Seattle, WA), diluted 1:2500 for 2 hours; Cx43 S368 (Millipore, St. Louis MO), diluted 1:3000 overnight; and total Cx43 (Sigma Corporation; St. Louis MO) diluted 1:3000 for 2 hours; and proteins were detected and non-specific binding was blocked with 5% fat-free milk in TBST (50 mmol/L Tris-HCl, pH 7.5, 0.15 mol/L NaCl, 0.05% Tween-20) for 2 hours at room temperature. Following five washes (1 x 5, 1 x 15, 3 x 5 minutes) with TBST, the membrane was incubated with either anti-rabbit (1:3000; Cell Signaling; Beverly, MA) or anti-mouse (1:300; GE Healthcare; Piscataway, NJ) HRP conjugated IgG for 1 hour. The membrane was again washed with TBST as stated above, and bound antibodies were detected with the enhanced chemiluminescence (ECL) reagent detection system (Thermo Scientific; Rockford, IL) or ECL+ (GE Healthcare; Piscataway, NJ) reagents, as described by Amersham Pharmacia Biotech (Arlington Heights, IL), and exposed to Hyperfilm (Amersham Pharmacia Biotech) according to the manufacturer’s instructions. β-actin was utilized as a loading control, as described previously Results were quantified by scanning densitometry (670 scanning densitometer, Bio-Rad Laboratories, Inc.) and expressed relative to standards on the same blot 1,2. All results were within the linear range for the antiserum and film in each case.

**Fura-2 [Ca^{2+}]i Imaging Studies:** Using protocols we previously reported and validated 2,3, P-UAECs were grown on 35-mm dishes to >90% density. P-UAECs were then treated with Fura-2AM (10μmol/L) in Krebs buffer (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM KH2PO4, 6 mM glucose, 2 mM CaCl2, and 25 mM HEPES, pH 7.4) and were imaged for a 5 minutes baseline and then stimulated by ATP (100μmol/L) and imaged for another 30 minutes 3. Cells were then washed with prewarmed (37 oC) Krebs buffer before covering them in Krebs buffer (2 ml final volume) and recovered for 20 minutes. Cells were subsequently treated with 1μmol/L or 1μmol/L 8-Bromo-cAMP or 8-Bromo-cGMP treatment for 30 minutes and re-stimulated with the same dose of ATP for the same duration time. Fura-2 loading was verified by viewing at 380 nm UV excitation on a Nikon Diaphot inverted microscope (InCyt Im2, Intracellular Imaging, Inc., Cincinnati, OH). A single isolated cell was then set in the field of view, and recordings commenced using alternate excitation at 340 and 380 nm at 25-msec intervals and measuring emitted light using a photomultiplier. From the ratio of emission at 510 nm detected at the two excitation wavelengths and by comparison to a standard curve established for the same settings using buffers of known free Ca^{2+}, the intracellular free Ca^{2+} was then calculated in real time using InCyt Im2 software on-line. Ca^{2+} bursts were counted before and after treatment as described previously 2,3.
References